According to the research report titled ‘Global voglibose Market Size study, by Category (Tablets, Capsules, Others) by End User(Hospital, Clinics, Drug Store, Others) and Regional Forecasts 2021-2027’, available with Market Study Report, global voglibose market size was worth USD 5.4 billion in 2020 and is expected to multiply at a CAGR of 7.2% over 2021-2027.
 

As per the findings of the report, increasing prevalence of diabetes, acquisitions and promotion strategies adopted by major players, along with technological advancements in healthcare are propelling global voglibose market growth.
 

For the unversed, voglibose is an alpha-glucosidase inhibitor that is used to lower post-prandial blood glucose levels in people who have diabetes. It delays glucose absorption, reducing the risk of macrovascular entanglements. Voglibose is crucial in the treatment of patients with impaired glucose tolerance and in the management of postprandial hyperglycemia.
 

Request sample copy of this Report:  Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3862701/

Citing a projection, India's diabetes population would rapidly increase from 21.7 million to 79.4 million by 2030. However, the prevalence is far higher than this evaluation, as many individuals are asymptomatic and unaware of the condition, allowing it to go unnoticed. This accounts for nearly a third of all analyzed cases. Similar scenario in other countries will continue to present new growth opportunities for business operating in this domain.
 

On the downside, individuals with allergies or any other major problem to any of the ingredients of the medicine are negatively impacting worldwide voglibose industry expansion.
 

Based on category, the market is categorized into capsules, tablets, and others. Moving on to end user scope, the industry segmentation comprises drug store, clinics, and hospital.
 

Elaborating on regional landscape, the key regions considered for the industry analysis are Latin America (Brazil, Mexico), Europe (Italy, Spain, France, Germany, United Kingdom), North America (United States, Canada), and Asia Pacific (South Korea, Australia, Japan, India, China).
 

Regionally, North America currently holds considerable portion of global voglibose market share, owing to growing elderly population, increasing research and development, and expeditious pressing administrations of medications.
 

Major contenders in global voglibose market sphere are Panacea Biotec Ltd., Neelkanth Healthcare (P)Ltd., Nexus Biotech, Life Care Pvt. Ltd., Blue Cross Laboratories Ltd., Strides Pharma Science Ltd., Three Dots Lifescience Pvt Ltd., Sarian Company Inc., AS Pharma Pvt Ltd., and Pfizer Inc.